Select Language

LILRA4

LILRA4 Overview

English Name	Leukocyte immunoglobulin-like receptor subfamily A member 4	Approved Drugs	0
Drugs in Clinical Trials	1	Target Synonym	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
Highest Development Stage	Phase 2 Clinical

English Name	Leukocyte immunoglobulin-like receptor subfamily A member 4
Target Synonym	ILT7，CD85g，Immunoglobulin-like transcript 7，LILRA4，Leukocyte Immunoglobulin Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (With TM Domain)， Member 4，CD85 Antigen-Like Family Member G，Leucocyte Ig-Like Receptor A4，Leukocyte Immunoglobulin-Like Receptor， Subfamily A (Without TM Domain)， Member 4，Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 4，CD85g Antigen，ILT-7
Approved Drugs	0
Drugs in Clinical Trials	1
Highest Development Stage	Phase 2 Clinical

LILRA4 Product List

Product Category
Protein (2)
Product Status
Launched (2)
Species
Human (2)
Tag
His Tag (2)
Conjugate
Unconjugated (2)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
LI4-H5243	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag (MALS verified)
LI4-H52H5	Human	HEK293	Human LILRA4 / CD85g / ILT7 Protein, His Tag

Total: 2

LILRA4 Background

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.

LILRA4 Synonyms

LILRA4,CD85g,ILT7,ILT-7

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Daxdilimab	MEDI-7734; VIB-7734; HZN-7734	Phase 2 Clinical	Horizon Therapeutics PLC, Sbi Biotech Co Ltd	Acute Lung Injury; Alopecia Areata; Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Lupus Nephritis; Myositis; Polymyositis; Scleroderma, Systemic; Sjogren's Syndrome	Details